Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

被引：141

作者：

Munchhof, Michael J. ^{[1
]}

Li, Qifang ^{[2
]}

Shavnya, Andrei ^{[2
]}

Borzillo, Gary V. ^{[2
]}

Boyden, Tracey L. ^{[2
]}

Jones, Christopher S.

LaGreca, Susan D. ^{[3
]}

Martinez-Alsina, Luis ^{[2
]}

Patel, Nandini ^{[2
]}

Pelletier, Kathleen ^{[2
]}

Reiter, Larry A. ^{[4
]}

Robbins, Michael D. ^{[5
]}

Tkalcevic, George T. ^{[2
]}

机构：

[1] Michael J Munchhof LLC, Salem, CT 06420 USA

[2] Pfizer Global Res & Dev, Groton, CT 06340 USA

[3] INC Res, Old Lyme, CT 06371 USA

[4] Reiter MedChem, Mystic, CT 06355 USA

[5] Bristol Myers Squibb Co, Princeton, NJ 08540 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 02期

关键词：

Smoothened; Hedgehog signaling pathway; PF-04449913; HEDGEHOG PATHWAY; BINDING;

D O I：

10.1021/ml2002423

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncology area due to the mounting evidence of their potential to provide promising therapeutic options for patients. Herein, we describe the discovery strategy to overcome the issues inherent in lead structure I that resulted in the identification of Smoothened inhibitor 14(2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (PF-04449913, 26), which has been advanced to human clinical studies.

引用

页码：106 / 111

页数：6

共 50 条

[21] Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
Curtin, ML
Florjancic, AS
Heyman, HR
Michaelides, MR
Garland, RB
Holms, JH
Steinman, DH
Dellaria, JF
Gong, J
Wada, CK
Guo, Y
Elmore, IB
Tapang, P
Albert, DH
Magoc, TJ
Marcotte, PA
Bouska, JJ
Goodfellow, CL
Bauch, JL
Marsch, KC
Morgan, DW
Davidsen, SK
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (12) : 1557 - 1560
[22] Discovery of BMS-562247, a potent and orally bioavailable coagulation factor Xa inhibitor
Pinto, DJP
Orwat, MJ
Fevig, JM
Quan, ML
Galemmo, RA
Koch, S
Li, RH
Clark, C
Cacciola, J
Wells, BL
Drummond, S
Rossi, KA
Alexander, RS
Luettgen, JM
Wong, PC
He, K
Xin, BM
Grossman, SJ
Knabb, RM
Ogletree, ML
Wexler, RR
Lam, PYS
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2646 - U2646
[23] Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist
Hoashi, Yasutaka
Takai, Takafumi
Kosugi, Yohei
Nakashima, Masato
Nakayama, Masaharu
Hirai, Keisuke
Uchikawa, Osamu
Koike, Tatsuki
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (06) : 3059 - 3074
[24] Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus
Fader, Lee
Brault, Martine
Desjardins, Jessica
Dansereau, Nathalie
Lamorte, Louie
Tremblay, Sonia
Bilodeau, Francois
Bordeleau, Josee
Duplessis, Martin
Gorys, Vida
Gillard, James
Gleason, James L.
James, Clint
Joly, Marc-Andre
Kuhn, Cyrille
Llinas-Brunet, Montse
Luo, Laibin
Morency, Louis
Morin, Sebastien
Parisien, Mathieu
Poirier, Maude
Thibeault, Carl
Thao Trinh
Sturino, Claudio
Srivastava, Sanjay
Yoakim, Christiane
Franti, Michael
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (05): : 525 - 530
[25] Discovery of potent and orally bioavailable macrocyclic FXIa inhibitors
Yang, Wu
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[26] A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Stem Cell Transplantation
Gutman, Jonathan A.
Denoncourt, Emily
Schatz, Derek
Smith, Clayton
Pollyea, Daniel Aaron
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S286 - S286
[27] Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells
Fukushima, Nobuaki
Minami, Yosuke
Hayakawa, Fumihiko
Kiyoi, Hitoshi
Sadarangani, Anil
Jamieson, Catriona H. M.
Naoe, Tomoki
BLOOD, 2013, 122 (21)
[28] Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase Inhibitor
Cee, Victor J.
Schenkel, Laurie B.
Hodous, Brian L.
Deak, Holly L.
Nguyen, Hanh N.
Olivieri, Philip R.
Romero, Karina
Bak, Annette
Be, Xuhai
Bellon, Steve
Bush, Tammy L.
Cheng, Alan C.
Chung, Grace
Coats, Steve
Eden, Patrick M.
Hanestad, Kelly
Gallant, Paul L.
Gu, Yan
Huang, Xin
Kendall, Richard L.
Lin, Min-Hwa Jasmine
Morrison, Michael J.
Patel, Vinod F.
Radinsky, Robert
Rose, Paul E.
Ross, Sandra
Sun, Ji-Rong
Tang, Jin
Zhao, Huilin
Payton, Marc
Geuns-Meyer, Stephanie D.
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (17) : 6368 - 6377
[29] Discovery of WX486 as a novel, potent, selective, and orally bioavailable irreversible inhibitor of BTK
Wu, Chengde
Shen, Chunli
Zhu, Yuchuan
Hu, Guoping
Lin, Jian
Chen, Shuhui
Xiao, Qiang
Huang, Lu
Chen, Hailiang
Tu, Ronghua
Xu, Yong
Wang, Xuehai
JOURNAL OF IMMUNOLOGY, 2016, 196
[30] From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors
Koravovic, Mladen
Mayasundari, Anand
Tasic, Gordana
Keramatnia, Fatemeh
Stachowski, Timothy R.
Cui, Huarui
Chai, Sergio C.
Jonchere, Barbara
Yang, Lei
Li, Yong
Fu, Xiang
Hiltenbrand, Ryan
Paul, Leena
Mishra, Vibhor
Klco, Jeffery M.
Roussel, Martine F.
Pomerantz, William CK.
Fischer, Marcus
Rankovic, Zoran
Savic, Vladimir
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 251

← 1 2 3 4 5 →